Chan joins 1315 Capital as a principal

Philadelphia-based growth equity firm 1315 Capital LLC has named Edward Chan as a principal. Previously, Chan worked at NaviMed Capital where he most recently served as a vice president. And prior to that, Chan was at Siemens Venture Capital where he evaluated and sourced healthcare deals.



1315 Capital, LLC, an expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies today announced the recent expansion of its team with the addition of Edward Chan. Mr. Chan joins Co-Founders, Adele Oliva and Michael Koby and brings to 1315 Capital extensive investing experience across late stage venture and lower middle market transactions.

“We are very excited to welcome Edward to 1315 Capital. He brings significant deal experience across our investment sectors and will focus on deal execution and portfolio management,” said Koby. “We have known Edward for over a decade when he first started his career in this industry and watched him build an established record of accomplishment.”

Prior to joining 1315 Capital, Mr. Chan spent nearly five years at NaviMed Capital, a lower middle market healthcare fund based in Washington, D.C. Most recently, he was a Vice President and focused on identifying and executing investments across healthcare services, healthcare IT and medical products. Prior to joining NaviMed Capital, Mr. Chan spent three years at Siemens Venture Capital. Based out of Boston and Beijing, he evaluated and sourced commercial and growth stage healthcare deals worldwide, performed research on various market sectors and supported portfolio companies.

While at NaviMed and Siemens, Mr. Chan was actively involved in the following investments: CenterPointe Behavioral Health System, Lucent Health Solutions, China Diagnostics Medical Corporation (sold to Actis Capital), BioImagene (sold to Roche), RadPharm (sold to JLL Partners), U-Systems (sold to GE), MD Datacor (sold to Noridian Mutual Insurance), Zonare (sold to Mindray), Sequenom (sold to LabCorp) and Cylex (sold to Viracor-IBT).

Mr. Chan also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. He started his career developing and commercializing a molecular diagnostic product at a venture backed company.

Mr. Chan received his B.S. in Biomedical Engineering from Johns Hopkins University and his M.B.A. in Healthcare Management and Finance from the Wharton School at the University of Pennsylvania.

About 1315 Capital
1315 Capital provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare service companies. The team believes these investment areas are attractive largely due to numerous niche market sub-segments and business models where high-quality management teams can rapidly grow small platform companies, in a capital efficient way, into large and important businesses that positively impact patients, physicians, and the broader healthcare system.

For more information, visit